Sinoway Industrial Co., Ltd.

Lacosamide 175481-36-4 Lacosamide 175481-36-4

Lacosamide 175481-36-4
Related Products
  • NanoActive alpha lipoic acid (ALA) 1077-28-7

    1.Basic information of NanoActive alpha lipoic acidProduct Name: NanoActive alpha lipoic acid (ALA)Other Names: NanoActive THIOOCTIC ACIDAppearance: yellow, viscous and transparent liquidTest Method: ...

  • NanoActive Astaxanthin 472-61-7

    1.Basic information of NanoActive AstaxanthinProduct Name: NanoActive AstaxanthinOther Names: NanoActive AstaAppearance: reddish to dark red, viscous and transparent liquidTest Method: HPLCCAS NO.: 47...

  • NanoActive Curcumin 458-37-7

    1.Basic information of NanoActive CurcuminProduct Name: NanoActive CurcuminOther Names: NanoActive turmeric extractAppearance: yellow, viscous and transparent liquidTest Method: HPLCCAS NO.: 458-37-7S...

Basic information of Lacosamide :

Name

Lacosamide

Alias

(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide

CAS NO.

175481-36-4

Molecular Formula

C13H18N2O3

Molecular Weight

250.29

EINECS

1308068-626-2

Brief Introduction

At present, there are more than 200,000 epilepsy patients in the world who have used lacosamide. Lacosamide is currently not approved in Japan or China for epilepsy treatment. 2012 UCB announced the launch of a Phase III clinical trial of lacosamide in Japan and China to study the efficacy and safety of lacosamide as an adjuvant therapy for adult patients with partial seizures. UCB obtained the rights to research on lacosamide in Japan at the end of 2010, and has since obtained worldwide rights to develop and sell lacosamide.

Storage condition

Room temperature, seal.


Use of Lacosamide:

Used in patients with ≥ 16-year-old epilepsy with or without secondary general attacks of partial seizure therapy. Antiepileptic effects are thought to regulate the slow inactivation of sodium channels, and their efficacy and tolerability have been shown in some randomized controlled trials. A single-center, large-scale cohort study found that the continuous use of lacosamide tablets for refractory epilepsy has a retention rate of 62% in one year, 45% in two years, and 35% in three years. 18% of patients reported significant reduction in seizures or episodes of cessation for more than 6 months during medication, with 4 episodes that stopped more than 1 year. Long-term efficacy is similar to zonisamide and pregabalin. The number of reported adverse events was 61%. The vast majority were associated with the central nervous system. Most are related to the central nervous system. Most clinical factors do not affect the retention rate, withdrawal is not due to adverse events, but often because of invalidity.

COA of Lacosamide :

Item

Standard

Result

Appearance

White powder

Conforms

Specific rotation

+15oC  to +17oC

+16.3 oC

Melting Point(/oC)

142-146oC

146 oC

Water(KP)

Not more than 0.5%

0.41%

Assay(HPLC)

Not less than 98.0%

98.27%

Conclusion

The product confirms to the standard


  • Oxaliplatin 61825-94-3
    Basic information of Oxaliplatin :Name OxaliplatinAliastrans-l-diaminocyclohexane oxalatoplatinum; oxalato(1r,2r-cyclohexanediammine)platinum(ii); oxalatoplatin; oxalatoplatinumCAS NO.61825-94-3Molecu... Oxaliplatin 61825-94-3
  • Nifuratel 4936-47-4
    asic information:Cas No.: 4936-47-4Molecular Formula: C10H11N3O5SMolecular Weight: 285.28Specification: Enterprise standard with 99.9% Appearance: Yellow Crystalline PowderUsage:Gynecological antibio... Nifuratel 4936-47-4
  • Esomeprazole Magnesium 217087-09-7
    Basic information:Other name: Esomeprazole magnesium trihydrate Bis(5-methoxy-2-[(S)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzylimidazole-1-yl) magnesium trihydrateCas no.: 217087-... Esomeprazole Magnesium 217087-09-7
  • Emtricitabine 143491-57-0
    Basic information of EmtricitabineNameEmtricitabineAliasEntricitabine;FTC;4-Amino-5-fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one;EMTRITABINE;EMTRICITABIN;SM-Q;CAS NO.143... Emtricitabine 143491-57-0

MORE_DETAIL Lacosamide 175481-36-4

Basic information of Lacosamide :

Name

Lacosamide

Alias

(2R)-2-acetamido-N-benzyl-3-methoxy-propanamide;(2R)-2-(Acetylamino)-3-methoxy-N-(phenylmethyl)propanamide;ADD 243037;Erlosamide;Harkoseride;SPM 927;(R)-2-Acetamido-N-benzyl-3-methoxypropanamide

CAS NO.

175481-36-4

Molecular Formula

C13H18N2O3

Molecular Weight

250.29

EINECS

1308068-626-2

Brief Introduction

At present, there are more than 200,000 epilepsy patients in the world who have used lacosamide. Lacosamide is currently not approved in Japan or China for epilepsy treatment. 2012 UCB announced the launch of a Phase III clinical trial of lacosamide in Japan and China to study the efficacy and safety of lacosamide as an adjuvant therapy for adult patients with partial seizures. UCB obtained the rights to research on lacosamide in Japan at the end of 2010, and has since obtained worldwide rights to develop and sell lacosamide.

Storage condition

Room temperature, seal.


Use of Lacosamide:

Used in patients with ≥ 16-year-old epilepsy with or without secondary general attacks of partial seizure therapy. Antiepileptic effects are thought to regulate the slow inactivation of sodium channels, and their efficacy and tolerability have been shown in some randomized controlled trials. A single-center, large-scale cohort study found that the continuous use of lacosamide tablets for refractory epilepsy has a retention rate of 62% in one year, 45% in two years, and 35% in three years. 18% of patients reported significant reduction in seizures or episodes of cessation for more than 6 months during medication, with 4 episodes that stopped more than 1 year. Long-term efficacy is similar to zonisamide and pregabalin. The number of reported adverse events was 61%. The vast majority were associated with the central nervous system. Most are related to the central nervous system. Most clinical factors do not affect the retention rate, withdrawal is not due to adverse events, but often because of invalidity.

COA of Lacosamide :

Item

Standard

Result

Appearance

White powder

Conforms

Specific rotation

+15oC  to +17oC

+16.3 oC

Melting Point(/oC)

142-146oC

146 oC

Water(KP)

Not more than 0.5%

0.41%

Assay(HPLC)

Not less than 98.0%

98.27%

Conclusion

The product confirms to the standard

Leave a Message Email Us

We will contact you within 24 hours.

  • TEL:+86-0592-5854962
  • FAX:+86-0592-5854960
  • EMAIL: xie@china-sinoway.com
  • ADDRESS:Floor 16, Huicheng Business Center, No. 839, Xiahe Rd., Siming Dist. Xiamen, Fujian, China
//